TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32858346
Drug: Trazodone 50
Normalized name: traZODone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 50 mg/d (TRAZ)
Study: 35165100
Drug: Sunitinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib treatment
Study: 36216827
Drug: Anti-angiogenic adjuvant
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-angiogenic adjuvant therapy
Study: 35297582
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group B (100 kV, 100 mA)
Study: 35297582
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group C (100 kV, 50 mA)
Study: 35297582
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group D (80 kV, 100 mA)
Study: 35297582
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group E (80 kV, 50 mA)
Study: 32164877
Drug: 131I-metuximab (27.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I-metuximab (27.75 MBq/kg) administered as a single transarterial injection 4-6 weeks after hepatectomy
Study: 32881138
Drug: 600 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/kg ALA
Study: 33674241
Drug: Add-on self-care
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add-on self-care therapy education
Study: 35979259
Drug: Saccharomyces cerevisiae
Normalized name: Saccharomyces cerevisiae
DrugBank: Saccharomyces cerevisiae (DB10447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces cerevisiae I-3856 (8 × 10^9 CFU daily)
Study: 32875658
Drug: Rotigotine 3
Normalized name: ROTIGOTINE 3MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 3 mg per day for 6 weeks
Study: 35999352
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody crizanlizumab
Study: 39037799
Drug: Sodium-glucose cotransporter-2
Normalized name: glucose / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-glucose cotransporter-2 inhibitors
Study: 35999352
Drug: Purinergic signaling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purinergic signaling receptor Y12 inhibitors
Study: 34795191
Drug: Dance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance therapy based on the Satir Model and group psychological intervention
Study: 35144974
Drug: Famotidine 80
Normalized name: ibuprofen/famotidine 800 mg-26.6 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 80 mg orally three times a day for 14 days
Study: 36273430
Drug: Multifamily therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifamily therapy (MFT) - 24 sessions in addition to treatment as usual (TAU)
Study: 36273430
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) - individual and family sessions
Study: 32333714
Drug: Rectal hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal hydrogel spacer
Study: 32333714
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no rectal hydrogel spacer)
Study: 35122485
Drug: Sham-extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham-extracorporeal shock wave therapy (sham-ESWT)
Study: 37354048
Drug: Dabigatran 75
Normalized name: dabigatran 75 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 75 mg
Study: 35770540
Drug: Auricular ASP
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular ASP needles treatment
Study: 35770540
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments (Control)
Study: 35242730
Drug: Azithromycin treatment
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin treatment (four biannual rounds)
Study: 35242730
Drug: Azithromycin treatment
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin treatment (two biannual rounds)
Study: 33950544
Drug: Tea Tree
Normalized name: tea tree
DrugBank: Melaleuca alternifolia leaf (DB14372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea Tree Oil (10% solution, 5 mL)
Study: 33950544
Drug: Alcohol (83%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (83% ethanol, 2 mL)
Study: 33950544
Drug: Benzalkonium Chloride
Normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzalkonium Chloride (0.8 mL)
Study: 32475274
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acid supplementation (9 g daily)
Study: 32475274
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose powder, 9 g daily)
Study: 34597713
Drug: PDS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS with ranibizumab 100 mg/ml with fixed 24‐week refill‐exchanges (PDS Q24W)
Study: 34597713
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5‐mg injections every 4 weeks (monthly ranibizumab)
Study: 32381807
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1% curcumin, 1% hyaluronidase, and 0.1% triamcinolone acetonide
Study: 32381807
Drug: Triamcinolone and
Normalized name: triamcinolone and antiseptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone and hyaluronidase mucoadhesive semisolid gel
Study: 34797287
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi exercise (TC) added to sodium hyaluronate treatment
Study: 36175588
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (VPA) 60 mg/kg/day for 3 days (D1-D3) followed by oral etoposide 50 mg once daily for two weeks (D4-D17)
Study: 36175588
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide (historical control)
Study: 34501728
Drug: Bilateral quadratus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral quadratus lumborum block type I with 24 mL 0.375% ropivacaine
Study: 34309117
Drug: Postoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative concurrent chemoradiotherapy (POCRT)
Study: 35491560
Drug: Warmed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed intravenous fluids (WIVF)
Study: 33839450
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel oral suspension
Study: 36002106
Drug: Conditioning regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning regimen (fludarabine 75 mg/m2, total body irradiation 12 Gy, cyclophosphamide 120 mg/kg)
Study: 33503193
Drug: Low-dose conjugated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose conjugated estrogen (CE) 0.3 mg
Study: 33503193
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Raloxifene + Low-dose CE)
Study: 32723723
Drug: ACT intervention
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT intervention via mobile phone messaging robot; twice-daily messages for 2 weeks post-surgery.
Study: 34459077
Drug: Augmented cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented cognitive behavioral therapy (CBT) adjunctive to treatment as usual (TAU)
Study: 35169036
Drug: Iberdomide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide (0.3 mg every other day, 0.3 mg once daily, 0.6 mg and 0.3 mg alternating once daily, or 0.6 mg once daily)
Study: 32819393
Drug: CAF3 (3-mg∙kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF3 (3-mg∙kg-1 of caffeine)
Study: 32819393
Drug: CAF6 (6-mg∙kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF6 (6-mg∙kg-1 of caffeine)
Study: 32819393
Drug: CON (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (no supplement)
Study: 35726368
Drug: Immediate titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate titrated intravenous oxytocin infusion and early amniotomy
Study: 34759152
Drug: Neutrophil/Lymphocyte (N/L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutrophil/Lymphocyte (N/L) ratio
Study: 33278897
Drug: Thermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal therapy
Study: 32502588
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 1% twice daily
Study: 38123875
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 1% once daily
Study: 32502588
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 0.5% twice daily
Study: 32502588
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 0.5% once daily
Study: 33608058
Drug: IVIg and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg and 1000 mg intravenous methylprednisolone (IVMP)
Study: 35817336
Drug: D 0.3
Normalized name: folic acid 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: D 0.3 μg·kg−1·h−1 dexmedetomidine
Study: 35817336
Drug: D 0.4
Normalized name: ozanimod 0.46 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: D 0.4 μg·kg−1·h−1 dexmedetomidine
Study: 35817336
Drug: D 0.5
Normalized name: folic acid 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: D 0.5 μg·kg−1·h−1 dexmedetomidine
Study: 35817336
Drug: D 0.6
Normalized name: salicylic acid 0.6 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: D 0.6 μg·kg−1·h−1 dexmedetomidine
Study: 32569125
Drug: All supplements
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All supplements
Study: 33734433
Drug: Standard-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose regimen (commencing at 25 μg)
Study: 33734433
Drug: Low-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose regimen (commencing at 12 μg)
Study: 32583013
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg yohimbine
Study: 32583013
Drug: Uncontrollability groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncontrollability groups (no control over shock administration)
Study: 85140364
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor specific for hepatitis B (TFdL-H) administered at 15-day intervals over a 6-month period
Study: 33092320
Drug: Carn‐βA (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carn‐βA (2.5 g L‐carnosine plus 2.5 g β‐alanine)
Study: 35078147
Drug: Standard European
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard European treatment protocol for LBP (control group)
Study: 34637608
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg) under fasted conditions
Study: 34637608
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg) under fed conditions (high-fat diet)
Study: 34637608
Drug: Rivaroxaban test
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban test formulation
Study: 34637608
Drug: Rivaroxaban reference
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban reference formulation (Xarelto)
Study: 36174434
Drug: Curcumin +
Normalized name: Nature's Truth Turmeric Curcumin + Ginger Gummies (Peach)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin + piperine (500 mg daily)
Study: 32683541
Drug: Ordered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordered treatment methods based on maximum-likelihood and robust estimation
Study: 33124927
Drug: Tic treatment
Normalized name: Detoxifying agents for antineoplastic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tic treatment
Study: 38608694
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg daily
Study: 32737923
Drug: Technosphere Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Technosphere Insulin (TI)
Study: 32706953
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg twice daily)
Study: 32706953
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg twice daily) plus Azithromycin (500 mg once daily for 7 days)
Study: 34031865
Drug: Conventional cardiovascular
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional cardiovascular drugs (ACE inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins)
Study: 34031865
Drug: Antithrombotics, pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotics, pulmonary vasodilators, RAAS‐related drugs, colchicine (ongoing RCTs)
Study: 34031865
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term anti‐atherogenic therapies (statins)
Study: 34031865
Drug: Current cardiovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current cardiovascular drugs
Study: 32822887
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - enoxaparin sodium 20 mg (2000 IU) twice a day for 1 week postoperatively
Study: 32822887
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (Control group)
Study: 32784157
Drug: Isotonic solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic solution (Control)
Study: 34573862
Drug: Fecal immunochemical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal immunochemical test (FIT) surveillance with annual FIT and colonoscopy if fecal hemoglobin concentration is ≥10 µg/g
Study: 35247964
Drug: Low-sodium (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium (3 g/d salt) + placebo
Study: 35247964
Drug: Medium-sodium (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-sodium (5 g/d salt) + spironolactone (SPL)
Study: 35247964
Drug: Low-sodium (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium (3 g/d salt) + spironolactone (SPL)
Study: 35167779
Drug: All sepetaprost
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All sepetaprost doses
Study: 33559053
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg daily for 21 days starting from day 1 in each cycle in addition to platinum-based chemotherapy
Study: 34168284
Drug: ixazomib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85)
Study: 34463842
Drug: Monthly ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly ranibizumab with targeted retinal photocoagulation (TRP)
Study: 34088700
Drug: Genetically instrumented
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically instrumented higher insulin resistance (IR)
Study: 34088700
Drug: Fasting insulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting insulin, glucose, or glycated hemoglobin
Study: 32204742
Drug: Model-predicted optimal
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-predicted optimal treatment
Study: 32204742
Drug: Model-predicted optimal
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-predicted optimal treatment (top 60% prediction)
Study: 32204742
Drug: Model-predicted optimal
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-predicted optimal treatment (conservative check)
Study: 33423837
Drug: Educational videos
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational videos about vaccines and small pharmacy-based financial incentives for vaccine receipt
Study: 32738365
Drug: Acupressure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure therapy in combination with pharmacological treatment (n = 106)
Study: 32738365
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment only (Control group, n = 106)
Study: 36217659
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive behavioral therapy (9 sessions over 8 weeks)
Study: 36217659
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with medication and vestibular rehabilitation (control group)
Study: 36217659
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive behavioral therapy
Study: 33638976
Drug: Empiric TB
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric TB therapy
Study: 32096209
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of red wine oligomeric procyanidins (OPCs)
Study: 32659699
Drug: Routine face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine face to face occupational therapy intervention (Control)
Study: 34697783
Drug: Ulmus macrocarpa
Normalized name: Ulmus rubra pollen
DrugBank: Ulmus rubra pollen (DB10985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulmus macrocarpa Hance extract (UME) 500 mg/day for 4 weeks
Study: 33151988
Drug: Indigo naturalis
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigo naturalis (IN) 500 mg, 5 capsules twice a day for 2 weeks
Study: 33492301
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg/d for 12 weeks
Study: 33317460
Drug: Oropharyngeal tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oropharyngeal tetracaine spray (Group S‐AIC)
Study: 34407970
Drug: Nivolumab (N)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (N) 240 mg every 2 weeks
Study: 34407970
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + Ipilimumab (N + I) 240 mg every 2 weeks + 1 mg/kg every 6 weeks
Study: 32622900
Drug: Cancer treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer treatments with statistically significant increase in overall survival
Study: 32622900
Drug: Cancer treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer treatments with overall survival as primary outcome
Study: 33231029
Drug: Standard PTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PTA treatment
Study: 33483110
Drug: Hypoventilation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoventilation therapy (TX, n = 20)
Study: 34545117
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics administered by paramedics
Study: 34488061
Drug: Dexmedetomidine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (intravenous 0.4 ?g/kg/h immediately after anesthesia induction and 0.1 ?g/kg/h after extubation, maintained until 24 h)
Study: 32917645
Drug: Calcium (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1,200 mg/day)
Study: 32917645
Drug: Calcium (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1,200 mg/day) in patients with DBP2 isoform
Study: 34129236
Drug: Dichlorphenamide (DCP)
DrugBank: Diclofenamide (DB01144)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dichlorphenamide (DCP) 50 mg twice daily
Study: 32711393
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training with resistive equipment (CTRE)
Study: 32711393
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training with multiple sets (CTMS)
Study: 32530339
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (1000 IU daily)
Study: 36288585
Drug: Ropivacaine 0.375%
Normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.375% and dexmedetomidine 1 mcg/kg
Study: 34797324
Drug: N-butylphthalide (NBP)
Normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-butylphthalide (NBP) therapy
Study: 32066898
Drug: Non-treatment visits
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment visits
Study: 32066898
Drug: Injection visits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection visits
Study: 34239102
Drug: Guidelines for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines for sample preparation, replication and randomization, quantification, recovery and recombination, ion suppression and peak misidentification
Study: 32517393
Drug: Dexmedetomidine-bupivacaine (DB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine-bupivacaine (DB) group (n = 40) - 30 mL bupivacaine 0.25% plus 1 mu g/kg dexmedetomidine
Study: 32517393
Drug: Bupivacaine (B)
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine (B) group (n = 40) - 30 mL bupivacaine 0.25% only